Literature DB >> 25646884

Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?

Marc-Antoine Allard1, Mylène Sebagh2, Aldrick Ruiz3, Catherine Guettier2, Bernard Paule4, Eric Vibert5, Antonio Sa Cunha1, Daniel Cherqui5, Didier Samuel5, Henri Bismuth4, Denis Castaing5, René Adam6.   

Abstract

BACKGROUND & AIMS: To investigate the prognostic significance of pathologic response (PR) after transarterial chemoembolization (TACE) in cirrhotic patients resected or transplanted for hepatocellular carcinoma (HCC), and to identify predictors of complete pathologic response (CPR).
METHODS: Between 1990 and 2010, 373 consecutive cirrhotic patients with HCC were treated by TACE followed by either liver resection (LR:184 patients) or liver transplantation (LT:189 patients). The PR was evaluated as the mean percentage of non-viable tumor area within each tumor. CPR was defined as the absence of any viable tumor area in all the present nodules.
RESULTS: A total of 59 (32%) and 37 (20%) patients had CPR after LR and LT, respectively. Five-year overall survival (OS) was higher in patients with CPR compared to those without, after LR (58% vs. 34%; p=0.0006) and tends to be higher after LT (84% vs. 65%; p=0.09). The 5-year recurrence-free survival (RFS) rates were significantly higher in both groups (24% vs. 13% after LR; p=0.008 and 94% vs. 73% after LT, p=0.007). A cut-off value of >90% necrosis emerged as an impacting factor on patient survival after LR or LT. On multivariate analysis stratified on the type of procedure (LR or LT), PR >90% remained an independent factor of better OS and RFS. Independent factors associated with CPR were: a maximal tumor size <30 mm (RR 2.17 [1.27-3.74]), a single tumor (RR 6.08 [3.29-12.07]), and an preoperative AFP<100 ng/ml (see results section) (RR 3.99 [1.63-11.98]). The probability to achieve a CPR ranged from 2% in the absence of any factors to 48% in the presence of all factors.
CONCLUSION: In cirrhotic patients with HCC, a complete or nearly complete PR improves long-term survival after LR and LT independently of other pathological factors. This underlines the importance of neoadjuvant treatment to obtain a significant decrease of active tumor load.
Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver resection; Liver transplantation; Pathologic response; Transarterial chemoembolization

Mesh:

Substances:

Year:  2015        PMID: 25646884     DOI: 10.1016/j.jhep.2015.01.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  34 in total

1.  Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it?

Authors:  Angelo Sangiovanni; Massimo Colombo
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

Review 2.  Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation.

Authors:  Umberto Cillo; Tommaso Giuliani; Marina Polacco; Luz Maria Herrero Manley; Gino Crivellari; Alessandro Vitale
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes.

Authors:  Chih-Che Lin; Chao-Long Chen
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

Review 4.  Bridging and downstaging therapy in patients suffering from hepatocellular carcinoma waiting on the list of liver transplantation.

Authors:  Wong Hoi She; Tan To Cheung
Journal:  Transl Gastroenterol Hepatol       Date:  2016-04-14

Review 5.  Bridging patients with hepatocellular cancer waiting for liver transplant: all the patients are the same?

Authors:  Martina Coletta; Daniele Nicolini; Andrea Benedetti Cacciaguerra; Susanna Mazzocato; Roberta Rossi; Marco Vivarelli
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-27

6.  Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?

Authors:  Dimitri Dorcaratto; Venkatesha Udupa; Niamh M Hogan; David P Brophy; Jeffrey W McCann; Donal Maguire; Justin Geoghegan; Colin P Cantwell; Emir Hoti
Journal:  Diagn Interv Radiol       Date:  2017 Nov-Dec       Impact factor: 2.630

Review 7.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

Review 8.  Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression?

Authors:  Jan Lerut; Samuele Iesari; Maxime Foguenne; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-10-12

9.  Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.

Authors:  Katherine S Cools; Andrew M Moon; Lauren M B Burke; Katrina A McGinty; Paula D Strassle; David A Gerber
Journal:  Liver Transpl       Date:  2019-12-20       Impact factor: 5.799

Review 10.  Hepatocellular carcinoma in children: hepatic resection and liver transplantation.

Authors:  Roberta Angelico; Chiara Grimaldi; Maria Cristina Saffioti; Aurora Castellano; Marco Spada
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.